文献速递药物相互作用

司库奇尤单抗不改变中重度银屑病患者CYP3A4底物咪达唑仑的药代动力学

Secukinumab Treatment Does Not Alter the Pharmacokinetics of the Cytochrome P450 3A4 Substrate Midazolam in Patients With Moderate to Severe Psoriasis.
PubMed 文献 · Clin Pharmacol Ther · 2019-08-03

这项开放标签疾病-药物-药物相互作用研究评估了司库奇尤单抗阻断IL-17A通路对CYP3A4敏感探针底物咪达唑仑PK的影响。24例中重度银屑病患者接受司库奇尤单抗300mg每周皮下注射,在治疗开始前及开始后7天和35天评估咪达唑仑PK。结果显示司库奇尤单抗虽降低下游炎症细胞因子,但对咪达唑仑PK无临床相关影响,提示其不太可能影响CYP3A4底物的PK。

要点

  • 司库奇尤单抗对CYP3A4底物咪达唑仑PK无临床相关影响。
  • IL-17A通路阻断不显著影响CYP3A4酶活性。
  • 司库奇尤单抗提供显著临床获益且总体耐受良好。

核心结论

  • 在中重度银屑病患者中阻断IL-17A信号不显著影响CYP3A4酶活性,司库奇尤单抗不太可能影响CYP3A4底物的PK。

研究设计与样本

  • 开放标签疾病-药物-药物相互作用研究,纳入24例中重度银屑病患者。
  • 司库奇尤单抗300mg每周皮下注射,在治疗开始前及开始后7天和35天评估咪达唑仑PK。

主要发现

  • 司库奇尤单抗表现出下游炎症细胞因子预期的降低。
  • 司库奇尤单抗对咪达唑仑PK无临床相关影响。
  • 司库奇尤单抗提供显著临床获益且总体耐受良好。

关键数值与推荐

  • 司库奇尤单抗300mg每周皮下注射。
  • 在治疗开始前及开始后7天和35天评估咪达唑仑PK。

临床怎么用

  • 使用司库奇尤单抗时,预计无需因CYP3A4酶活性改变而调整经CYP3A4代谢药物的剂量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This open-label disease-drug-drug interaction study assessed whether blockade of the interleukin (IL)-17A pathway by secukinumab and subsequent downregulation of inflammatory cytokines like IL-6 or high-sensitivity C-reactive protein affects the pharmacokinetics (PKs) of a sensitive probe substrate of the cytochrome P450 3A4 isoform (CYP3A4). The PKs of midazolam, metabolized by CYP3A4, was evaluated before and after 7 and 35 days of treatment initiation of subcutaneous secukinumab at a dose of 300 mg weekly in 24 patients with moderate-to-severe psoriasis. Although demonstrating the expected decrease in downstream inflammatory cytokines, secukinumab had no clinically relevant effects on the PKs of midazolam, provided substantial clinical benefit, and was generally well tolerated. In summary, blockade of IL-17A signaling in patients with moderate-to-severe psoriasis does not significantly affect CYP3A4 enzyme activities and, therefore, the use of secukinumab is unlikely to influence the PKs of CYP3A4 substrates.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Bruin G, Hasselberg A, Koroleva I, et al. Secukinumab Treatment Does Not Alter the Pharmacokinetics of the Cytochrome P450 3A4 Substrate Midazolam in Patients With Moderate to Severe Psoriasis. Clin Pharmacol Ther. 2019. PMID: 31228872. doi:10.1002/cpt.1558

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。